Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists - In vitro characterisation

Amino Acids

Volumn 19, Issue 1, 2000, Pages 157-166

  Parsons, C G ^a   Danysz, W ^a   Quack, G ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Amino acids; Memantine; MRZ 2 579; N Methyl D aspartate; Uncompetitive antagonist

Indexed keywords

1 AMINO 1,3,3,5,5 PENTAMETHYLCYCLOHEXANE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; UNCLASSIFIED DRUG;

BINDING AFFINITY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; CYCLOPENTANES; EXCITATORY AMINO ACID ANTAGONISTS; IN VITRO; MEMANTINE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE;

ANIMALIA;

EID: 0033806040     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007260070044     Document Type: Review

References (40)

1. Trapping of glutamate and glycine during open channel block of rat hippocampal neuron NMDA receptors by 9-aminoacridine
2. Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2
3. Trapping channel block of NMDA-activated responses by amantadine and memantine
4. Different binding affinities of NMDA receptor channel blockers in various brain regions-indication of NMDA receptor heterogeneity
5. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells
6. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine - Therapeutic advantage against NMDA receptor-mediated neurotoxicity
7. Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications
8. Glutamate in CNS disorders: A revived target for drug development?
9. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies
10. The uncompetitive NMDA receptor antagonists MRZ 2/579 and memantine have a similar in vitro - TI: LTP and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices
11. 2+ in hippocampal slices
12. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices
13. Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic / hypoglycaemic excitotoxicity in hippocampal slices
14. ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: Neuroprotection against mitochondrial metabolic toxicity and regional pharmacology
15. Subunit selective block of cloned NMDA receptors by the anticonvulsant drug felbamate
16. Pharmacokinetics of uncompetitive NMDA receptor antagonist, MRZ 2/579 in comparison to it's in vitro potency in electrophysiological studies
17. Evidence for lysosomotropism of memantine in cultured human cells - Cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission
18. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: Insights into the mechanism of action
19. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: Binding and patch clamp studies
20. 2+ block of recombinant NMDA channels mutated within the selectivity filter and expressed in Xenopus oocytes
21. Differences in degree of trapping between AR-R15896 and other uncompetitive NMDA receptor antagonists
22. Prospects for clinically tolerated NMDA antagonists - Open-channel blockers and alternative redox states of nitric oxide
23. Antagonism of N-methyl-D-aspartate-evoked currents in cortical cultures by ARL 15896AR
24. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block
25. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)
26. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo
27. Glutamate in CNS Disorders as a target for drug development: An update
28. The amino-alkyl-cyclohexane MRZ 2/579 is an uncompetitive NMDA Receptor antagonist with fast blocking kinetics and strong voltage-dependency
29. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: In vitro and in vivo characterization
30. Memantine is a clinically well tolerated NMDA receptor antagonist - A review of preclinical data
31. Memantine does not show intracellular block of the NMDA receptor channel
32. Regional variations in the pharmacology of NMDA receptor channel blockers: Implications for therapeutic potential
33. Therapeutic potential of excitatory amino acid antagonists - Channel blockers and 2,3-benzodiazepines
34. Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D-aspartate antagonist (+/-)-5-aminocarbonyl-10,11-dihydro-5H-dibenzocyclohepten-5, 10-imine (ADCI) - Comparison with the structural analogs Dizocilpine (MK-801) and carbamazepine
35. Two blocking sites of amino-adamantane derivatives in open N-methyl-D-aspartate channels
36. Interaction of memantine and amantadine with agonist-unbound NMDA- Receptor channels in acutely isolated rat hippocampal neurons
37. Subtype selectivity of memantine, amantadine and MRZ 2/579 on NMDA receptors expressed in Xenopus oocytes
38. Memantine blocking kinetics on NR1a/NR2A receptors studied using voltage steps and concentration clamp in inside / outside-out patches from Xenopus oocytes
39. 2+ permeable channels
40. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP